Page last updated: 2024-08-21

indazoles and cyc 202

indazoles has been researched along with cyc 202 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berdini, V; Boulstridge, JA; Carr, MG; Cross, DM; Davis, DJ; Devine, LA; Early, TR; Feltell, RE; Lewis, EJ; McMenamin, RL; Navarro, EF; O'Brien, MA; O'Reilly, M; Reule, M; Saxty, G; Seavers, LC; Smith, DM; Squires, MS; Trewartha, G; Walker, MT; Woodhead, AJ; Woolford, AJ; Wyatt, PG	1
Chou, KC	1
Gao, C; Gao, L; Luo, X; Yan, J; Zhao, C; Zhao, J; Zhao, W; Zhu, X	1

Reviews

1 review(s) available for indazoles and cyc 202

Article	Year
Graphic rule for drug metabolism systems. Current drug metabolism, 2010, Volume: 11, Issue:4 Topics: Adamantane; Animals; Benzimidazoles; Enzymes; Humans; Indazoles; Models, Theoretical; Nitriles; Pharmaceutical Preparations; Protein Folding; Purines; Pyrrolidines; Roscovitine; Time Factors; Vildagliptin	2010

Other Studies

2 other study(ies) available for indazoles and cyc 202

Article	Year
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. Journal of medicinal chemistry, 2008, Aug-28, Volume: 51, Issue:16 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Mice; Piperidines; Pyrazoles; Structure-Activity Relationship	2008
Cdk5 is required for the neuroprotective effect of transforming growth factor-β1 against cerebral ischemia-reperfusion. Biochemical and biophysical research communications, 2017, 04-15, Volume: 485, Issue:4 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain Ischemia; Cell Differentiation; Cell Proliferation; Cyclin-Dependent Kinase 5; Indazoles; MAP Kinase Signaling System; Neurites; Neuroprotective Agents; PC12 Cells; Piperazines; Protein Kinase Inhibitors; Purines; Rats; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Roscovitine; Transforming Growth Factor beta1	2017

Article

Year

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

Journal of medicinal chemistry, 2008, Aug-28, Volume: 51, Issue:16

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Mice; Piperidines; Pyrazoles; Structure-Activity Relationship

2008

Cdk5 is required for the neuroprotective effect of transforming growth factor-β1 against cerebral ischemia-reperfusion.

Biochemical and biophysical research communications, 2017, 04-15, Volume: 485, Issue:4

Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain Ischemia; Cell Differentiation; Cell Proliferation; Cyclin-Dependent Kinase 5; Indazoles; MAP Kinase Signaling System; Neurites; Neuroprotective Agents; PC12 Cells; Piperazines; Protein Kinase Inhibitors; Purines; Rats; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Roscovitine; Transforming Growth Factor beta1

2017